Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin.

Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding patient choice and streamlining diabetes care workflows. PALO ALTO, Calif., ...

Abbott Laboratories ABT recently presented late-breaking data on its FreeStyle Libre system at the American Diabetes Association’s (“ADA”) 81st Scientific Sessions. Data showed that this continuous ...

This morning Abbott revealed that its much anticipated integrated continuous glucose monitoring system the FreeStyle Libre 2 is now FDA cleared for adults and kids over the age of 4 with diabetes. The ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...

(RTTNews) - Abbott Laboratories {ABT) said that new data showed its continuous glucose monitoring technology, FreeStyle Libre System, significantly reduced HbA1C levels in people with type 2 diabetes ...

Data at the American Diabetes Association 82 nd Scientific Sessions show Abbott's FreeStyle Libre 3 system is first and only 14-day continuous glucose monitor (CGM) system to achieve a mean absolute ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a new data integration with continuous glucose monitoring (CGM ...